Elasmogen develops therapeutics for autoimmune diseases and cancer based on single-domain antibodies derived from sharks.

Elasmogen

Elasmogen is a therapeutic biologics company developing multi-functional products for difficult-to-treat diseases. The company has built a product pipeline that exploits the advantages of its proprietary, patent protected soloMER technology including first-in-class drug conjugates (SDC) and bi-specific products for the treatment of autoimmune diseases.
Our oncology assets include a pipeline of differentiated soloMER-targeted RadioPharmaceutical Therapies (RPT) for the treatment of solid tumour cancers.

Innovate UK

Scottish Government

Scottish Investment Bank

Deepbridge Capital

Elasmogen Ltd

Delighted to see Elasmogen highlighted, amongst all the other biopharma companies developing drugs for IBD, in Beacon and Hanson Wade's excellent webinar (link below). Our scientific team are dedicated to developing, new effective multi-functional therapies for autoimmune disease including a first-in-class soloMER drug conjugate and an orally delivered bi-specific product.
Exciting times ahead as we progress these therapies into the clinic.

#soloMERs #IBD #autoimmunedisease #lifesciences #biotech 

https://lnkd.in/eEyGjJHr

Our CEO, Caroline Barelle was delighted to contribute to Connect: Health Tech's "The Connectivity Mix: Insights on unlocking innovation: the power of the connectivity mix to transform health tech' report".

Connectivity and diversity are key to building a healthy and effective ecosystem to drive innovation. 

https://lnkd.in/grMdEj8

 #ConnectivityMix #JoinTheDots #Lifesciences #ecosystem

We had a great time hosting Harlaw Academy’s advanced higher biology students. The students participated in interactive theory and practical sessions learning from Elasmogen’s scientists about fundamental ELISA and PCR techniques.

A great piece by Helen Pattison about the positive and long-lasting impact that securing an Innovate UK Biomedical Catalyst grant had on the evolution and growth of the company and the wonderful Elasmogen team.

#ukri #bmc #lifesciences #soloMERs #biologics #scottishbusiness 

https://lnkd.in/epbBXZnZ

Our CEO, Caroline Barelle will be attending LSX's annual Inv€$tival Showcase taking place on 13th November and the Jefferies London Healthcare Conference from the 14th-16th November, London.

Please connect on the partnering portal or directly at info@elasmogen.com if you would like to meet up to learn more about our incredible soloMER technology.

https://lnkd.in/eE_QBbD

#lsx #jeffries #lifesciences #soloMERs #biologics

Yesterday The Times and ONE hosted the 3rd iteration of the Life Sciences Summit at the beautiful Old Aberdeen campus of The University of Aberdeen. 
Elasmogen's Chief Executive Caroline Barelle and BGF investor Lucy Edwardes-Jones shared with the audience their discussion about long-term funding relationships. Thanks Caroline and Lucy for the great panel and engaging conversation!
All discussions and panels from the Life Sciences Summit were recorded and will be shared soon.

https://lnkd.in/eRpQpXm6

Metric
Company Name	Elasmogen
Symbol
MSH ID	COM:ELASMOGEN
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	GB
Stage
Employee Count	17
Website	elasmogen.com
LinkedIn	elasmogen-ltd
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ELASMOGEN

Elasmogen

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue